Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Fundamental & Clinical Pharmacology

• Publication date

  2005-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1472-8206.2005.00356.xPMID 16176337
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An Introduction to the Bootstrap

  2007cited by this paper
• Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.

  2003cited by this paper
• J-Shaped Relationship between Blood Pressure and Mortality in Hypertensive Patients: New Insights from a Meta-Analysis of Individual-Patient Data

  2002cited by this paper
• Cardiovascular protection and blood pressure reduction: a meta-analysis.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Blood-pressure reduction and cardiovascular risk in HOPE study.

  2001cited by this paper
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

  2000cited by this paper
• Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

  2000cited by this paper
• Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.

  1999cited by this paper
• Criteria for the validation of surrogate endpoints in randomized experiments.

  1998cited by this paper
• Assessing treatment-time interaction in clinical trials with time to event data: a meta-analysis of hypertension trials.

  1998cited by this paper
• Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

  1998cited by this paper
• Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

  1996cited by this paper
• INDANA: a meta-analysis on individual patient data in hypertension. Protocol and preliminary results.

  1995cited by this paper
• Measurement Error in Nonlinear Models

  1995cited by this paper
• Medical Research Council trial of treatment of hypertension in older adults: principal results.

  1992cited by this paper
• Statistical validation of intermediate endpoints for chronic diseases.

  1992cited by this paper
• Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

  1991cited by this paper
• Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension)

  1991cited by this paper
• Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

  1990cited by this paper
• Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

  1990cited by this paper
• Surrogate endpoints in clinical trials: definition and operational criteria.

  1989cited by this paper
• Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study.

  1989cited by this paper
• The Australian Therapeutic Trial in Mild Hypertension.

  1987cited by this paper
• Randomised trial of treatment of hypertension in elderly patients in primary care.

  1986cited by this paper
• Mortality and Morbidity Results from the European Working Party on High Blood Pressure in the Elderly Trial

  1986cited by this paper
• MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party.

  1985cited by this paper
• Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial.

  1985cited by this paper
• The Australian therapeutic trial in mild hypertension.

  1984cited by this paper
• Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group.

  1982cited by this paper
• Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. Hypertension Detection and Follow-up Program Cooperative Group.

  1979cited by this paper
• EVALUATION OF DRUG TREATMENT IN MILD HYPERTENSION: VA‐NHLBI FEASIBILITY TRIAL *

  1978cited by this paper
• Regression models and life tables (with discussion

  1972cited by this paper

• Pharmacotherapy for hypertension in adults 60 years or older.

  2025cites this paper
• Exposure to the Chinese famine in early life and self-reported arthritis risk in adulthood

  2021cites this paper
• First-line drug classes for hypertension in adults: a network meta-analysis

  2020cites this paper
• Pharmacotherapy for hypertension in adults 60 years or older.

  2019cites this paper
• Association between difference in blood pressure reduction and risk of cardiovascular events in a type 2 diabetes population: A meta-regression analysis.

  2019cites this paper
• First-line drugs for hypertension.

  2018cites this paper
• Pharmacotherapy for hypertension in adults aged 18 to 59 years.

  2017cites this paper
• Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension.

  2016cites this paper
• Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?

  2015cites this paper
• Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?

  2014cites this paper
• Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial

  2014cites this paper
• Blood pressure targets for hypertension in people with diabetes mellitus.

  2013cites this paper
• Expected impact of a public health intervention in the presence of synergistic risk factors.

  2013cites this paper
• Is blood pressure reduction a valid surrogate endpoint for stroke prevention? an analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the biomarker-surrogacy (BioSurrogate) evaluation

  2012cites this paper
• Modeling the impact of cardiovascular prevention strategies: toward better information for public health decisions.

  2012cites this paper
• The IDEAL study : towards personalized drug treatment of hypertension.

  2012cites this paper
• First line treatment for uncomplicated hypertension: time for a rethink.

  2011cites this paper
• The Role of Beta-Blockers as First-Line Therapy in Hypertension

  2011cites this paper
• An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill (“Polypill”) in People with Raised Cardiovascular Risk

  2011cites this paper
• An International Randomised Placebo-Controlled Trial of a Four-Component Combination Pill ( ‘ ‘ Polypill ’ ’ ) in People with Raised Cardiovascular Risk

  2011cites this paper
• Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting enzyme inhibitors?

  2009cites this paper
• Angiotensin AT1-receptor blockers and cerebrovascular protection: do they actually have a cutting edge over angiotensin-converting

  2009cites this paper
• First-line drugs for hypertension.

  2009cites this paper
• Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.

  2008cites this paper
• Copper and silver wiring in hypertensive retinopathy.

  2006cites this paper
• Estimation of attributable burden of disease: authors' reply.

  2006cites this paper
• The lower the better: does simplicity lead to absurdity?

  2006cites this paper